Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2022-01-04 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于自愿披露公司相关产品获得美国FDA批准注册的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of FDA approval for a product. It includes details about the product, its approval status, potential risks, and impact on profits. The document is short (1196 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory event related to product approval rather than a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-04 Chinese
圣湘生物科技股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase (buyback) activities. It details the number of shares repurchased, prices, total funds used, and compliance with relevant regulations. The document does not contain financial statements or earnings data but focuses on the update of the share buyback program. This matches the description of a Transaction in Own Shares (POS) filing, which reports on the company's repurchase of its own shares.
2022-01-03 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司2021年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring securities company (西部证券股份有限公司) regarding its on-site inspection and continuous supervision work for the company 圣湘生物科技股份有限公司 during the 2021 fiscal year. It covers governance, internal controls, information disclosure, independence, related party transactions, use of raised funds, and other compliance aspects. The document includes findings, interviews, and verification of company operations and compliance with regulatory requirements. It is not an announcement or a brief summary but a substantive supervisory report. This matches the definition of an Audit Report / Information (AR), which includes standalone audit or supervisory reports and results of regulatory checks, excluding full annual reports. The document length (2555 characters) is consistent with a detailed report but not a full annual report. There is no indication it is an Annual Report (10-K) or other categories such as management changes or earnings releases. Therefore, the classification is AR with high confidence. FY 2021
2022-01-03 Chinese
圣湘生物科技股份有限公司关于自愿披露公司相关检测产品获得欧盟卫生安全委员会HSC common list白名单注册的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of a product obtaining registration on the EU Health Security Committee's common list whitelist. It discusses product details, competitive risks, and profit impact uncertainties. The document is relatively short (2140 characters) and does not contain financial statements or detailed financial data. It is an announcement about a regulatory approval related to product certification and market status, not a financial report or earnings release. There is no indication of board changes, voting results, or legal proceedings. The content fits best under a general regulatory announcement category rather than a specific financial report or meeting material. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-12-22 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company 圣湘生物科技股份有限公司 regarding the receipt of a medical device registration certificate issued by the National Medical Products Administration. It describes the certificate details, product information, potential impact on the company, and risk warnings. The document is short (872 characters) and serves as an announcement of a regulatory approval rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-17 Chinese
圣湘生物科技股份有限公司关于持股5%以上股东减持的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder's reduction in holdings, specifically a shareholder reducing their stake by 1,200,000 shares, with detailed information on share quantities and percentages before and after the transaction. It explicitly states it is a "提示性公告" (a notice or announcement) about a shareholder holding more than 5% reducing shares. There is no financial statement, no report or analysis, and the document is short (1386 characters). This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is not a full report, nor an earnings release or capital change announcement. Therefore, the correct classification is MRQ with high confidence.
2021-12-15 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.